Cura AJ, Carruthers A. AMP kinase regulation of sugar transport in brain capillary endothelial cells during acute metabolic stress. Am J Physiol Cell Physiol 303: C806 -C814, 2012. First published July 3, 2012; doi:10.1152/ajpcell.00437.2011.-AMP-dependent kinase (AMPK) and GLUT1-mediated sugar transport in blood-brain barrier endothelial cells are activated during acute cellular metabolic stress. Using murine brain microvasculature endothelium bEnd.3 cells, we show that AMPK phosphorylation and stimulation of 3-O-methylglucose transport by the AMPK agonist AICAR are inhibited in a dosedependent manner by the AMPK antagonist Compound C. AMPK ␣1-or AMPK ␣2-knockdown by RNA interference or AMPK inhibition by Compound C reduces AMPK phosphorylation and 3-O-methylglucose transport stimulation induced by cellular glucose-depletion, by potassium cyanide (KCN), or by carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone (FCCP). Cell surface biotinylation studies reveal that plasma membrane GLUT1 levels are increased two-to threefold by cellular glucose depletion, AICAR or KCN treatment, and that these increases are prevented by Compound C and by AMPK ␣1-or ␣2-knockdown. These results support the hypothesis that AMPK activation in blood-brain barrier-derived endothelial cells directs the trafficking of GLUT1 intracellular pools to the plasma membrane, thereby increasing endothelial sugar transport capacity. blood brain barrier; endothelial cells; glucose transport; membrane; metabolism THE ADULT MAMMALIAN BRAIN uses glucose as its primary energy source. While brain function and development require a constant glucose supply, diffusional exchange of glucose between blood and brain is severely restricted by the blood-brain barrier. This barrier comprises a nonfenestrated, endothelium formed by capillary endothelial cells connected by tight junctions. Glucose that enters the brain must, therefore, cross the endothelium by protein-mediated trans-cellular transport. In mammalian brain, this is catalyzed by the glucose transport protein GLUT1, which is expressed in luminal and abluminal membranes of microvasculature endothelial cells and is essential for brain metabolic homeostasis (13, 15, 30, 36, 43) .
THE ADULT MAMMALIAN BRAIN uses glucose as its primary energy source. While brain function and development require a constant glucose supply, diffusional exchange of glucose between blood and brain is severely restricted by the blood-brain barrier. This barrier comprises a nonfenestrated, endothelium formed by capillary endothelial cells connected by tight junctions. Glucose that enters the brain must, therefore, cross the endothelium by protein-mediated trans-cellular transport. In mammalian brain, this is catalyzed by the glucose transport protein GLUT1, which is expressed in luminal and abluminal membranes of microvasculature endothelial cells and is essential for brain metabolic homeostasis (13, 15, 30, 36, 43) .
Under resting conditions and at physiologic blood glucose levels, GLUT1-mediated glucose transport across the bloodbrain barrier barely exceeds brain glucose utilization (42) . Under conditions where glucose consumption could exceed glucose supply, for example during hypoglycemia, hypoxia, or intense neuronal activation, blood-brain barrier glucose transport capacity is increased by two different mechanisms. During chronic metabolic stress [e.g., hypoxia (24) and hypoglycemia (4, 33) ], endothelial cell GLUT1 gene and protein expression increases in vitro (3) and in vivo (5) , thereby increasing blood-brain barrier sugar transport. In contrast, acute metabolic stress [e.g., short-lived hypoglycemia, hypoxia, metabolic poisoning (14) , or seizures (10, 35) ] is without effect on GLUT1 expression but promotes recruitment of intracellular GLUT1 to the plasma membrane (16) , thereby increasing blood-brain barrier sugar transport (14) . The signals that regulate bloodbrain barrier sugar transport during acute metabolic stress are not known.
Phosphorylated AMP-activated kinase (AMPK) plays a key role in maintaining energy homeostasis in skeletal muscle (19, 45) , heart (12, 32), brain (29, 37, 40) , and endothelial cells (17) by switching cellular metabolism to lowered ATP consumption and increased ATP production. AMPK regulates glycolysis, fatty acid oxidation, and glucose transport (11, 22, 23) , the activity of cell surface GLUT1 (1, 2) in cultured rat liver Clone-9 cells and translocation of the insulin-sensitive glucose transporter GLUT4 to the plasma membrane in heart and muscle (25) .
Aglycemia, hypoxia, and oxygen glucose deprivation activate AMPK in primary bovine brain microvascular endothelial cells (44) . Several forms of acute metabolic stress, including glucose starvation, KCN or FCCP treatment induce AMPK phosphorylation and sugar transport stimulation (14) in the cultured brain microvascular endothelial cell line bEnd.3 (34) . These observations establish that immortalized and primary cultures of cerebral microvasculature endothelial cells share a common response to cellular metabolic stress but do not directly address the role of AMPK activation in controlling GLUT1-mediated sugar uptake. In the present study, we employ AMPK agonists and antagonists and AMPK small interfering (si)RNAs to perturb AMPK signaling. Our results strongly suggest that AMPK directs the trafficking of GLUT1 between endothelial cell membrane and intracellular pools and thereby regulates blood-brain barrier endothelial cell sugar transport in response to altered cellular metabolic status.
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EXPERIMENTAL PROCEDURES
Tissue culture. bEnd.3 cells were obtained from American Type Culture Collection (Manassas, VA) and maintained in Dulbecco's modified Eagle's medium (DMEM) from Gibco supplemented with 10% fetal bovine serum (FBS) from Hyclone and 1% penicillinstreptomycin (Pen-Strep) solution (Gibco) at 37°C in a humidified 5% CO 2 incubator as described previously (14) .
Antibodies. A custom, affinity-purified rabbit polyclonal antibody raised against a synthetic peptide corresponding to GLUT1 amino acids 480 -492 was produced by New England Peptide. Rabbit polyclonal and monoclonal antibodies against AMPK and phosphorylated AMPK (P-Thr172), and phosphorylated acetyl-CoA carboxylase (ACC) (P-Ser79) were obtained from Cell Signaling Technology, and an antibody against cyclophilin B was obtained from Abcam. Horseradish peroxidase-conjugated goat anti-rabbit secondary antibody was obtained from Jackson Immunoresearch.
Buffers. Cell lysis buffer consisted of 5 mM HEPES, 5 mM MgCl2, 150 mM NaCl, 50 M EDTA, and 1% SDS. Uptake stop solution included 10 M cytochalasin B (Sigma) and 100 M phloretin (Sigma) in Dulbecco's phosphate-buffered saline (DPBS). TBS was composed of 20 mM Tris base and 135 mM NaCl, pH 7.6. TBST comprised TBS buffer with 0.2% Tween 20. Biotin Quench solution was composed of 250 mM Trizma Base. Biotin lysis buffer contained TBS with 0.5% Triton X-100.
Western blotting of bEnd.3 cells. Confluent 100 mm dishes of bEnd.3 cells were treated with 2 mM AICAR (ThermoFisher) or 2 mM AICAR plus 1, 2, 5, 10, or 20 M Compound C (Tocris Bioscience) for 2 h. Cells were then washed twice with DPBS, lysed, and analyzed for total protein concentration using a Micro BCA kit (Pierce). Western blot analyses were performed as previously described (14) using a 1:1,000 dilution of either rabbit AMPK P-Thr172, rabbit ACC P-Ser79 antibody, or a 1:10,000 dilution of rabbit cyclophilin B antibody. Samples were run in triplicate, and band densities were quantitated using ImageJ software (National Institutes of Health, Bethesda, MD).
Knockdown of AMP kinase in bEnd.3 cells. Pools of four separate siRNA oligonucleotides targeting the mouse AMPK subunits ␣1 and ␣2, as well as cyclophilin B, and a pool of nonsilencing siRNA were obtained from Dharmacon. The cationic lipid transfection reagent Dharmafect 4, RNase-free water, and siRNA resuspension buffer were also obtained from Dharmacon.
To knock down AMPK and cyclophilin B in bEnd.3 cells, confluent 100 mm dishes were split into 6-or 12-well tissue culture dishes at a ratio of 1:3 the night before each knockdown. After cells were verified as 70 -80% confluent, growth media were replaced with DMEM ϩ 10% FBS but lacking Pen-Strep. Oligonucleotide-Dharmafect complexes were prepared in DMEM without FBS or Pen-Strep. Dharmafect and the siRNA were allowed to equilibrate with the media for 5 min before being combined and allowed to complex for 20 min. Following the complexing step, each well of cells was treated with a total 4 l of Dharmafect 4 alone or 4 l of Dharmafect 4 and 100 nmol total siRNA for 48 h. For AMPK knockdowns, each well contained 50 nmol each of AMPK ␣1 and ␣2 siRNA for a total of 100 nmol. Knockdown was verified by Western blotting using antibodies for AMPK and cyclophilin B.
3-OMG uptake measurements in bEnd.3 cells. Uptake was measured for 30 s at 4°C as previously described (14) using 20 mM 3-O-methylglucose (3-OMG) containing 2.5 Ci/ml
Sugar uptake measurements in AICAR-treated cells were performed as described above with the following modifications: on the day of the assay, cells were placed in serum-free DMEM or serum-free DMEM containing either 0 or 2 mM AICAR or 2 mM AICAR plus 1, 2, 10, or 20 M Compound C for 2 h at 37°C. Cells were washed with 1 ml of either glucose-free DPBS, DPBS containing 2 mM AICAR, or DPBS containing 2 mM AICAR plus Compound C, at which point uptake was measured.
Sugar uptake in metabolically poisoned and glucose-depleted cells was measured as described above with the following modifications: cells were placed in serum-free DMEM Ϯ 10 M Compound C, serum-free DMEM containing 2 mM AICAR Ϯ 10 M Compound C for 2 h, or serum-free DMEM Ϯ 10 M Compound C for 1.5 h followed by serum-free glucose-free DMEM Ϯ 10 M Compound C for 30 min. Cells were washed with 1 ml of either glucose-free DPBS, or glucose-free DPBS plus the appropriate poison (AICAR, KCN, or FCCP) Ϯ 10 M Compound C at which point uptake was measured. For AMPK knockdown experiments, cells were treated with siRNA against the ␣1-and ␣2-subunits of AMPK for 48 h before measurement of sugar uptake. Cells were then prepared and processed as previously described.
Biotinylation of bEnd.3 cells. Biotinylation was carried out as previously described (14) with the following modifications: 100 mm plates of confluent bEnd.3 cells were placed in serum-free DMEM with 2 mM AICAR Ϯ 10 M Compound C for 2 h, 2 mM AICAR Ϯ 10 M Compound C for 1.5 h followed by serum-free, glucose-free DMEM Ϯ 10 M Compound C for 30 min, or 5 mM KCN Ϯ 10 M Compound C for 10 min at 37°C before proceeding with biotinylation. For AMPK knockdown experiments, cells were split into 100 mm dishes before AMPK knockdown, and cells were treated with siRNA or Dharmafect alone as previously described for 48 h before biotinylation. On the day of the experiment, plates were treated with 5 mM KCN for 10 min at 37°C, then biotinylated and processed as previously described.
Data analysis. Differences in sugar transport, cell surface GLUT1 biotinylation, or AMPK phosphorylation in control and test conditions were analyzed by using Student's t-test.
RESULTS
Compound C inhibits AICAR-dependent AMPK phosphorylation.
AMPK is activated by phosphorylation of AMPK threonine 172 (22) and this phosphorylation is inhibited in bovine brain microvasculature endothelial cells by Compound C (44) . To analyze Compound C inhibition of AMPK activity in bEnd.3 cells, we treated cells with 2 mM AICAR to activate AMPK in the absence or presence of increasing concentrations of Compound C. Thr172 phosphorylation was analyzed by using an AMPK-phospho-Thr172-specific antibody ( We also examined phosphorylation of ACC, a direct downstream target of AMPK (21) . Using an antibody specific to phosphorylated Ser79 on ACC, we measured AICAR-stimulated ACC phosphorylation in the presence of increasing Compound C concentration ([Compound C]) (Fig. 1, C and D) . Compound C reduces ACC phosphorylation in a dose-dependent manner with K i(app) ϭ 2.9 Ϯ 1.2 M. Both AMPK and ACC are phosphorylated in the absence of AICAR, suggesting either that untreated bEnd.3 cells experience a low, but measurable level of metabolic stress or that there is a low level of AMPK and ACC phosphorylation independent of metabolic stress.
Compound C inhibits AICAR-stimulated 3-OMG uptake. The facilitative glucose transport protein GLUT1 mediates sugar transport in control and AICAR-treated bEnd.3 cells where AICAR increases V max for 3-OMG net uptake by twofold (14) . We therefore asked whether AICAR stimulation of transport is suppressed by Compound C.
bEnd.3 cells were treated with 2 mM AICAR plus increasing concentrations of Compound C, and uptake of 20 mM 3-OMG was measured over 30 s at 4°C (Fig. 2) . 3-OMG is a nonmetabolizable GLUT1 substrate whose net uptake proceeds until intracellular [3-OMG] ϭ extracellular [3-OMG] and unidirec-tional 3-OMG uptake and exit are quantitatively identical. Net uptake at 30 s achieves only 9% and 20% equilibration in control and FCCP-treated cells, respectively (14) , indicating that transport determinations at 30 sc underestimate steadystate transport rates by Ͻ7%. In the present study, AICAR Acute metabolic stress-induced AMPK phosphorylation is reduced with Compound C treatment and AMPK knockdown. Treatment of bEnd.3 cells with siRNA oligonucleotides targeting mouse AMPK subunits ␣1 plus ␣2 reduces AMPK expression by 2.2-fold. Treatment with cyclophilin B siRNAs and a pool of nonsilencing siRNAs is without effect on bEnd.3 AMPK expression (Fig. 3, A-D) . The use of isoform-specific AMPK siRNAs indicates that message knockdown by AMPK ␣1 or ␣2 siRNA is specific and is not accompanied by upregulation of the nontargeted AMPK isoform (Fig. 4, A and B) .
Pretreatment of cells with AMPK-targeted siRNAs for 48 h reduces acute stress-induced AMPK phosphorylation. Cells were treated with AICAR, 5 mM KCN, 8 g/ml FCCP, 10 M Compound C, or glucose starved, and assayed for AMPK phosphorylation by Western blot analysis (Fig. 5A) . Quantitation of band densities (Fig. 5B ) reveals that basal AMPK phosphorylation is reduced by 72% following siRNA treatment. The responses to glucose deprivation, AICAR, Compound C, KCN, and FCCP treatments are reduced by 25%, 70%, 71%, 53%, and 46%, respectively, following siRNA treatment. AMPK knockdown is incomplete (Figs. 3A and 5A ) and the question remains as to whether the residual AMPK, which continues to respond to metabolic stress (Fig. 5, A and  B) , is sufficient to activate glucose transport.
Compound C inhibits acute metabolic stress-induced AMPK activation in endothelial cells. We subjected bEnd.3 cells to 2 mM AICAR (10 min), glucose starvation (30 min), 5 mM KCN (10 min), or 8 g/ml FCCP (10 min) in the absence or presence of Compound C, and assayed AMPK phosphorylation by Western blot analysis. An untreated control was measured for basal AMPK phosphorylation (Fig. 5C) . Quantitation of phosphorylation (Fig. 5D) indicates that all stress conditions and AICAR treatment increase AMPK phosphorylation by 4-to 10-fold. Cells treated with only Compound C show no significant increase in phosphorylation over controls. Compound C treatment reduces stress-induced AMPK phosphorylation by 36% in glucose-starved cells, 56% in AICAR-treated cells, 69% in KCN-treated cells, and 61% in FCCP-treated cells. Although AMPK phosphorylation was reduced in the presence of Compound C, complete phosphorylation inhibition was not observed.
Compound C and AMPK knockdown inhibit metabolic stressinduced 3-OMG uptake stimulation. We next asked whether inhibition of AMPK phosphorylation suppresses sugar uptake stimulation during metabolic stress. 3-OMG uptake was measured in bEnd.3 cells in the absence and presence of 10 M Compound C in cells that were glucose starved, treated with 2 mM AICAR, treated with 5 mM KCN, or treated with 8 g/ml FCCP as described above. 3-OMG uptake (Fig. 6A) is stimulated 2.6-fold in glucose-starved cells, 2.6-fold in AICARtreated cells, 2.9-fold in KCN-treated cells, and 3.0-fold in FCCP-treated cells. Glucose transport in control cells is also stimulated 1.9-fold by 10 M Compound C. Compound C inhibits 3-OMG uptake by 40% in glucose-starved cells, 42% in AICAR-treated cells, by 54% in KCN-treated cells, and by 64% in FCCP-treated cells (Fig. 6A) .
In cells where AMPK is knocked down before measurement of 3-OMG uptake, stress-induced stimulation of uptake is also reversed (Fig. 6B) . Mock-transfected and AMPK knockdown cells not subjected to stress show no appreciable increase in 3-OMG uptake over control cells. Nontransfected cells treated with AICAR, KCN, FCCP, or cells subjected to glucose starvation all show a two-to threefold increase in 3-OMG uptake. This stimulation of sugar uptake is reversed to near-control levels in AMPK knockdown cells. AMPK knockdown inhibits 3-OMG uptake by 48% in glucose-starved cells, by 41% in AICARtreated cells, by 50% in KCN-treated cells, and by 43% in FCCP-treated cells (Fig. 4B ). Compound C stimulates 3-OMG uptake 1.3-fold, but AMPK knockdown has no effect on this stimulation. The use of nonsilencing siRNAs or mock transfection protocols are without effect on basal sugar uptake or KCN-stimulated sugar uptake (Fig. 6, A and B) . All subsequent AMPK siRNA experiments therefore used mock transfection as the appropriate control.
The use of AMPK ␣1 or ␣2 siRNAs specifically reduces AMPK ␣1 or ␣2 message expression, respectively (Fig. 4) . We therefore asked which AMPK isoform is required for stressinduced sugar transport stimulation in bEnd.3 cells. Transport stimulation by glucose deprivation or by KCN treatment is blocked by AMPK ␣1 knockdown, by AMPK ␣2 knockdown, and by knockdown of AMPK ␣1 plus ␣2 (Fig. 6C) . We therefore conclude that both AMPK ␣1 and ␣2 are required for sugar transport stimulation during metabolic stress.
Compound C and AMPK knockdown inhibit GLUT1 recruitment during acute metabolic stress. bEnd.3 sugar transport stimulation during acute metabolic stress is mediated by recruitment of intracellular GLUT1 to the plasma membrane (14) . The role of AMPK in this process was evaluated by examining the effects of Compound C on GLUT1 recruitment. Cells were treated with 2 mM AICAR, glucose starved, or KCN treated as described above in the absence or presence of 10 M Compound C. Cells were then washed, cooled to 4°C, and treated with the membrane-impermeant Sulfo-NHS-SSBiotin to label exposed primary amines (lysine side-chains) as described previously (14) . The reaction was quenched, the cells were lysed in detergent-containing lysis buffer, and biotinylated proteins were precipitated with streptavidin beads. Precipitated proteins were analyzed by Western blotting using anti- GLUT1 COOH-terminal IgGs (Fig. 7, A, C , and E) and band densities were quantitated (Fig. 7, B, D, and F) . As recently reported (14) , biotinylated, COOH-terminal-reactive GLUT1 is revealed as a 48-kDa species plus a broadly mobile 55-kDa species. Occasionally, a 42-kDa species is also observed (Fig.  7, C and E) . Treatment of membranes with peptide:N-glycosidase F causes all species to collapse to a 40-to 42-kDa GLUT1 species (14) . Cell surface expression of the 48-kDa GLUT1 COOH-terminal antibody reactive species is unchanged by AICAR, whereas expression of the 55-kDa species is increased by 2-to 3-fold (Fig. 7, B and F) . Glucose depletion and KCN appear to enhance cell surface expression of the 48-and 55-kDa species by 2-to 4-fold. AICAR treatment increases total plasma membrane GLUT1 by approximately 2.1-fold, glucose depletion by approximately 3.0-fold, and KCN treatment by approximately 1.8-to 2.4-fold over controls. These results mirror the increases in 3-OMG transport capacity produced by metabolic poisons. In contrast, Compound C-treated cells show no significant change in plasma membrane GLUT1 (Fig. 7, B, D, and F) .
AMPK knockdown before KCN treatment also prevents GLUT1 recruitment to the plasma membrane. KCN treatment increases GLUT1 at the plasma membrane 1.8-to 2.4-fold over mock transfected cells, but this recruitment is blocked in AMPK knockdown cells treated with KCN. Basal plasma membrane [GLUT1] is unaffected by AMPK knockdown (Fig.  7, G and H) . These data are consistent with the results obtained by Compound C inhibition of AMPK in Fig. 7 , E and F. Biotinylation of cell surface GLUT1 is increased 2.2-fold following glucose deprivation of mock-transfected cells but is unchanged following glucose deprivation of cells previously transfected with AMPK siRNA (data not shown).
DISCUSSION
This study examines the hypothesis that AMPK modulates GLUT1-mediated sugar uptake in brain microvascular endothelial cells by regulating plasma membrane GLUT1 levels Ordinate, 3-OMG uptake (dpm per g total cell protein). Abscissa, experimental condition. Data represent means Ϯ SE of three separate experiments. A t-test analysis indicates as follows: *P Ͻ 0.005, all test conditions (minus Compound C) show significantly greater uptake than control; §P Ͻ 0.005, Compound C reduces sugar uptake in all instances except in control cells, where uptake is significantly increased. B: AMPK siRNA inhibition of modulated 3-OMG uptake. Cells were treated with or without AMPK siRNAs for 48 h. Before cooling to 4°C, glucose depletion, and transport initiation, cells were treated for 15 min at 37°C with 5 mM glucose (control), 0 glucose, 5 mM KCN, 8 g/ml FCCP, 10 M compound C, or for 2 h with 2 mM AICAR. Uptake of 20 mM 3-OMG was then measured for 30 s in each condition. Ordinate, 3-OMG uptake (dpm per g total cell protein). Abscissa, experimental condition. Data represent means Ϯ SE of three separate experiments. A t-test analysis indicates as follows: *P Ͻ 0.005, all test conditions (minus AMPK siRNA) show significantly greater uptake than control; sugar uptake by mock-transfected control cells, by control cells transfected with nonsilencing siRNAs and by compound C (CC)-treated cells Ϯ AMPK siRNA is not significantly different from uptake by control cells (P Ͼ 0.19); §P Ͻ 0.005, AMPK siRNA transfection reduces sugar uptake in all test conditions. C: effects of AMPK ␣1-and ␣2-specific siRNAs on sugar transport stimulation by glucose deprivation or KCN treatment. Cells were treated with or without AMPK ␣1, AMPK ␣2, or AMPK ␣1 ϩ ␣2 siRNAs for 48 h. Before cooling to 4°C, glucose depletion, and transport initiation, cells were treated for 15 min at 37°C with 5 mM glucose (control), 0 glucose, or 5 mM KCN. Uptake of 20 mM 3-OMG was then measured for 30 s in each condition. Ordinate, 3-OMG uptake (dpm per g total cell protein). Abscissa, experimental condition. Data represent means Ϯ SE of three separate experiments. A t-test analysis indicates as follows: *P Ͻ 0.005, all test conditions lacking siRNAs show significantly greater uptake than control; all conditions with siRNAs are not significantly different from control. during acute metabolic stress. We show that endothelial cell AMPK is phosphorylated during metabolic stress and that this is inhibited in a dose-dependent manner by the AMPK antagonist, Compound C. AMPK activation by the AMPK agonist AICAR or by metabolic stress is associated with stimulation of GLUT1-mediated sugar uptake; but transport stimulation is inhibited by AMPK knockdown and in a dose-dependent manner by Compound C. Transport stimulation appears to result from recruitment of intracellular GLUT1 to the cell surface because Compound C and AMPK knockdown block AICAR-and metabolic stress-induced GLUT1 recruitment.
Compound C is a high-affinity ligand that competes with AMP and ATP for binding to AMPK (47) . ATP-and Compound C-liganded AMPK is catalytically inactive, but AMPbinding promotes AMPK phosphorylation, resulting in activation (22, 23) . ZMP, an AICAR metabolite, also binds at the AMP-binding site to activate the kinase (22) . Compound C and ZMP binding are thus mutually exclusive, thereby explaining 
Our previous work shows that AICAR application to bEnd.3 cells and ATP depletion-induced acute metabolic stress promote AMPK phosphorylation and increased sugar uptake (14) . While inferring a link between AMPK activation and sugar transport stimulation, these findings do not establish causality. The present study demonstrates that the AMPK inhibitor Compound C inhibits AMPK activation and sugar transport stimulation. While pharmacological inhibition of a target protein can produce unforeseen side effects, the observation that AMPK knockdown also prevents metabolic stress-induced sugar transport stimulation validates the use of Compound C as an effective AMPK inhibitor. The concordance between the results of pharmacologic and knockdown approaches further implicates AMPK as the mediator of GLUT1 translocation to the plasma membrane during acute stress. Metabolic stressinduced AMPK phosphorylation (particularly that promoted by KCN and FCCP) is never completely ablated by Compound C treatment or AMPK knockdown. Nonetheless, Compound C or AMPK knockdown inhibits KCN-and FCCP-induced 3-OMG uptake stimulation. This result implies that there is a threshold of AMPK activation below which phosphorylation of AMPK is not sufficient to stimulate GLUT1 recruitment to the plasma membrane.
Compound C does not directly inhibit GLUT1-mediated bEnd.3 cell sugar transport. In fact, 3-OMG uptake is stimulated 1.3-to 1.9-fold by Compound C. This may result from a previously well-characterized, independent regulatory mechanism (6 -8, 27, 28) in which GLUT1-adenine nucleotide interactions allosterically modify sugar transport activity. ATP binding to GLUT1 reduces V max and K m for sugar uptake, while AMP displaces ATP from GLUT1, converting the protein to a high-capacity low-affinity transporter. Compound C may compete with intracellular ATP for binding to GLUT1, thereby reversing allosteric inhibition of transport and increasing sugar uptake. If this interpretation of Compound C-stimulation of basal sugar transport is correct, this suggests that basal sugar transport in endothelial cells is subject to tonic, allosteric inhibition by cytoplasmic ATP. The lack of effect of AMPK knockdown on basal sugar transport and on Compound C-stimulated sugar transport reinforces the view that Compound C stimulation of transport is AMPK independent and suggests that basal glucose transport in cultured bEnd.3 cells is not activated by basal AMPK phosphorylation. Compound C and AMPK knockdown significantly attenuate stimulation of sugar uptake and AMPK phosphorylation by metabolic stress. Cell surface GLUT1 recruitment is completely blocked by Compound C and AMPK knockdown, while AMPK knockdown in the absence of stress has no appreciable effect on GLUT1 localization. These data, in conjunction with our previous findings (14) , strengthen the hypothesis that AMPK activation mediates bEnd.3 cell sugar transport stimulation during metabolic stress.
Chronic metabolic stress causes increased GLUT1 expression and increased sugar transport in brain microvascular endothelial cells (4, 5, 24, 26, 33, 41) . In contrast, acute metabolic stress is without effect on GLUT1 expression but increases cellular sugar transport capacity (9, 10, 14) . The present work supports the hypothesis that activation of AMPK [the primary sensor in cellular energy homeostasis (22, 23) ] stimulates sugar transport by rapidly enhancing GLUT1 trafficking to the plasma membrane. AMPK also regulates GLUT4-mediated sugar transport in muscle and adipose by chronic control of gene expression and by acute regulation of protein trafficking to the plasma membrane (1, 18, 25, 46) . AMPK therefore plays a dual role in each tissue by initiating short-term responses to acute changes in metabolic state and long-term responses to chronic alterations in cellular metabolism.
Glucose is a primary energy source for the brain, and its transport across the blood-brain barrier is rate-limiting for cerebral glucose utilization (31, 42) . When a region of the brain becomes acutely activated or when blood glucose levels rapidly fall, local blood flow and glucose uptake are activated to maintain brain glucose availability (4, 5, 26, 33, 39, 41) . The present study supports the hypothesis that elevated intracellular AMP promotes endothelial cell AMPK phosphorylation, which leads to intracellular GLUT1 translocation to luminal and abluminal membranes. The net effect is increased glucose transport across the blood-brain barrier and enhanced glucose delivery to astrocytes and neurons.
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